Watch Community Respiratory Therapists Jacqueline Turvey and Joanne Terry for an interactive discussion on the benefits of Airway Clearance Therapy (ACT), and why this non-pharmacological treatment should be integrated into the action plans of patients dealing with COPD.
This conversation explores:
✓ The face of COPD in Canada
✓ The link between excess mucus and COPD exacerbations
✓ How to integrate a non-pharmacological approach into your patient's treatment plan
✓ Airway Clearance Therapy (ACT) and how it works
✓ How to manage mucus with OPEP therapy
✓ Tips for overcoming obstacles &am
Join Dr. Sacha Bhinder, HBSc, MD, FRCPC, for a review of inhaled delivery device products that are available in Canada, and how to foster customized care when choosing the most appropriate device for your patient.
Joignez-vous à David Gourde, Inf. et CRE, pour une discussion sur comment vous pouvez aider vos patients à libérer leurs poumons avec un traitement non-pharmacologique.
Cette session a été établie en partenariat avec Alliance Pharma.
Votre conférencier : David Gourde, Inf. B. Sc. CRE Intervenant pivot-réseau en maladies pulmonaires chroniques
Joignez-vous à Dr. Claude Poirier, Pneumologue, pour une discussion sur la santé respiratoire et comment vous pouvez aider vos patients à mieux respirer et améliorer leur qualité de vie avec une approche non-pharmacologique.
As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.
This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
From a UK perspective, BUD/F delivered via an MDI + VHC offers an economic benefit for the treatment of patients with mild asthma. Further analysis is required to determine if there would be any quality-adjusted life-year (QALY) effects based on the chosen intervention.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
Asthma impacts different people in different ways. Most people are able to control their asthma with regular use of their controller medication and using their reliever medication when necessary. However, for many it can be difficult to recognize when their asthma is not controlled. When asthma is well-controlled, you will experience little to no asthma symptoms.
The most efficient and effective delivery method remains that recommended in the device IFU (one actuation inhaled at a time, as well inhalation as soon as possible after actuation)
However, this laboratory-based study has indicated that a modified common-canister protocol with an anti-static VHC as the aerosol transfer vehicle has the potential to be a viable ‘off-label’ proposition in hospital situations where there is an urgent need to conserve pMDI medication as well as avoid cross-contamination from pathogenic viruses or bacteria
Evaluations of inhaler use have demonstrated that mishandling of MDIs is commonplace.
One of the most common errors is the failure to coordinate inhalation with actuation of the inhaler
One of the reasons why VHCs are often prescribed, is to reduce the severity of this error
This Functional Respiratory Imaging (FRI) based study assessed the likely severity of a short inhalation delay (from actuation) with an MDI alone and how it contrasted to the use with a VHC
Nontuberculous mycobacterial (NTM) lung disease is a chronic, progressive condition caused by nontuberculous mycobacteria. NTM lung disease occurs more frequently in older adults and people with other lung diseases, like bronchiectasis, and chronic obstructive pulmonary disease (COPD).
Cystic fibrosis (CF) is a progressive, genetic condition affecting more than 100,000 people worldwide.1 There are over 4,300 people living with CF in Canada.2
